Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity

Surgery for Obesity and Related Diseases

Volumn 4, Issue 5, 2008, Pages 625-631

  Borkgren Okonek, Marilyn J ^a,b   Hart, Robert W ^a,b   Pantano, John E ^a,b   Rantis Jr , Peter C ^b,c   Guske, Paul J ^b,c   Kane Jr , James M ^b,c   Gordon, Nancy ^d   Sambol, Nancy C ^e  

^a Suburban Lung Associates   (United States)

^b ALEXIAN BROTHERS MEDICAL CENTER   (United States)

^c Suburban Surgical Care Consultants   (United States)

^d Gordon and Associates   (United States)

^e PharmacoLogics   (United States)

Author keywords

Antifactor Xa activity; Enoxaparin thromboprophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; ESTROGEN; HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ASTHMA; BLOOD TRANSFUSION; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LAPAROSCOPIC SURGERY; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; OPEN STUDY; OPERATION DURATION; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; SLEEP APNEA SYNDROME; STOMACH BYPASS; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTITHROMBIN III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GASTRIC BYPASS; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; OBESITY, MORBID; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 51349153010     PISSN: 15507289     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soard.2007.11.010     Document Type: Article

References (32)

1. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl (2004) 338S-400S
2. Blaszyk H., and Bjornsson J. Factor V Leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg 135 (2000) 1410-1413
3. Brolin R.E. Gastric bypass. Surg Clin North Am 81 (2001) 1077-1095
4. Sapala J.A., Wood M.H., Schuhknecht M.P., and Sapala M.A. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg 13 (2003) 819-825
5. Bern M.M., Bothe A., Bistrian B., Batist G., Haywood E., and Blackburn G. Effects of low-dose warfarin on antithrombin III levels in morbidly obese patients. Surgery 94 (1983) 78-83
6. De Pergola G., and Pannaccuilli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25 (2002) 899-905
7. Hirsch J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl (2004) 188S-203S
8. Wu E.C., and Barba C.A. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg 10 (2000) 7-13
9. Shepherd M.F., Rosborough T.K., and Schwartz M.L. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 13 (2003) 249-253
10. Scholten D.J., Hoedema R.M., and Scholten S.E. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 12 (2002) 19-24
11. Hamad G.G., and Choban P.S. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 15 (2005) 1368-1374
12. Gonzalez R., Haines K., Nelson L.G., Gallagher S.F., and Murr M.M. Predictive factors of thromboembolic events in patients undergoing Roux-en-Y gastric bypass. Surg Obes Relat Dis 2 (2006) 30-36
13. Abou-Nukta F., Alkhoury F., Arroyo K., et al. Clinical pulmonary embolus after gastric bypass surgery. Surg Obes Relat Dis 2 (2006) 24-29
14. Hubbard V.S., and Hall W.H. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Draft Statement. Obes Surg 1 (1991) 257-265
15. Hamad G.G., Ikramuddin S., Fernstrom J.D., Bontempo F., and Schauer P.R. Recommended dosing of enoxaparin for thromboprophylaxis is subtherapeutic in the morbidly obese. (abstract). Obes Surg 12 (2002) 478
16. Kraus S., Wallace J.R., Andris D.A., et al. Efficacy of body mass index (BMI) dependent dosing of enoxaparin in gastric bypass (GBP) patients. (abstract). Obes Surg 12 (2002) 203
17. Sanderink G.J., Le Liboux A., Jariwala N., et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72 (2002) 308-318
18. Podnos Y.D., Jimenez J.C., Wilson S.E., Stevens C.M., and Nguyen N.T. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg 138 (2003) 957-961
19. Higa K.D., Boone K.B., and Tienchin H. Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients-what have we learned?. Obes Surg 10 (2000) 509-513
20. DeMaria E.J., Sugerman H.J., Kellum J.M., Meador J.E., and Wolfe L.G. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg 235 (2002) 630-647
21. Sugerman H.J., Sugerman E.L., Wolfe L., Kellum Jr. J.M., Schweitzer M.A., and DeMaria E.J. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. Ann Surg 234 (2001) 41-46
22. Melinek J., Livingston E., Cortina G., and Fishbein M.C. Autopsy findings following gastric bypass surgery for morbid obesity. Arch Pathol Lab Med 126 (2002) 1091-1095
23. Miller M.T., and Rovito P.F. An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg 14 (2004) 731-737
24. Quebbeman B., Akhonzadeh M., and Dallal R. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg 15 (2005) 1221-1224
25. Prystowsky J.B., Morasch M.D., Eskandari M.D., et al. Prospective analysis of the incidence of deep vein thrombosis in bariatric surgery patients. Surgery 138 (2005) 759-765
26. Carmody B.J., Sugerman H.J., Kellum J.M., et al. Pulmonary embolism complicating bariatric surgery: detailed analysis of a single institution's 24-year experience. J Am Coll Surg 203 (2006) 831-837
27. Frederiksen S.G., Hedenbro J.L., and Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 90 (2003) 547-548
28. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against VTE with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
29. Spaw A.T., and Husted J.D. Bleeding after laparoscopic gastric bypass: case report and literature review. Surg Obes Relat Dis 1 (2005) 99-103
30. Nguyen N.T., Rivers R., and Wolfe B.E. Early gastrointestinal hemorrhage after laparoscopic gastric bypass. Obes Surg 13 (2003) 62-65
31. Buchwald J., Avidor Y., Braunwald E., et al. Bariatric surgery: a systemic review and meta-analysis. JAMA 292 (2004) 1724-1737
32. Cendan J.C., Abu-aouf D., Gabrielli A., et al. Utilization of intensive care resources in bariatric surgery. Obes Surg 15 (2005) 1247-1251